Acrux (ASX:ACR), the Australian company with patient-preferred technology for delivering drugs across the skin, today announced an agreement with the New York-based Population Council, Inc. The agreement enables Acrux to progress toward commercialization of a unique contraceptive spray, containing the new-generation contraceptive drug Nestorone®.
